R&D Pipeline

R&D Pipeline (In-House)

As of November 2021

Product Name
/ Generic Name
/ Development Code
Expected Indications Category Development Stage Development Classification
TAVNEOS®
/ Avacopan
Microscopic polyangiitis Granulomatosis with polyangiitis Selective C5a receptor antagonist Approved In-licensed /
Vifor Fresenius Medical Care Renal Pharma (Switzerland)
Carotegrast Methyl
/ AJM300
Ulcerative colitis Alpha 4 integrin receptor antagonist NDA In-licensed /
Co-development with EA Pharma (Japan)
Rovatirelin
/ KPS-0373
Spinocerebellar ataxia TRH receptor agonist Preparation of submission In-licensed /
Shionogi (Japan)
Fostamatinib
/ R788
Chronic idiopathic thrombocytopenic purpura Tyrosine kinase inhibitor Phase III In-licensed /
Rigel Pharmaceuticals (U.S.)
Difelikefalin
/ MR13A9
Uremic pruritus in dialysis patients Kappa opioid receptor agonist Phase III In-licensed /
Co-development with Maruishi Pharmaceutical (Japan)
CG0070 Non-muscle-invasive bladder cancer Oncolytic Viral Therapy Phase III In-licensed /
CG Oncology (U.S.)
Linzagolix
/ KLH-2109
Endometriosis GnRH receptor antagonist Phase II Kissei
KDT-3594 Parkinson's disease Dopamine receptor agonist Phase II Kissei
KSP-0243 Inflammatory bowel disease Phase I Kissei




R&D Pipeline (Out-Licensing)

As of November 2021

Generic Name
/ Development Code
Expected Indications Category Countries & Regions Development Company Development Stage
Linzagolix Uterine fibroids GnRH receptor antagonist EU, US ObsEva SA (Switzerland) NDA
Endometriosis EU, US Phase III
Uterine fibroids, Endometriosis China Bio Genuine (China) Preparation for Clinical Trial
Silodosin Dysuria associated with benign prostatic hyperplasia Alpha 1A adrenergic receptor antagonist Vietnam, etc. Eisai (Japan) NDA
KDT-3594 Parkinson's disease Dopamine receptor agonist China, etc. AffaMed (China) Phase II
Bedoradrine Acute exacerbation of asthma Beta 2 adrenergic receptor agonist US MediciNova (U.S.) Phase II
Fostamatinib Chronic idiopathic thrombocytopenic purpura Tyrosine kinase inhibitor Korea JW Pharmaceutical (Korea) Preparation for Clinical Trial
China, etc. Inmagene Biopharmaceuticals (China) Preparation for Clinical Trial